SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Arkema S.A. (ARKAY) trades at a trailing P/E of 89.1, forward P/E of 14.9. Trailing earnings yield is 1.12%, forward earnings yield 6.70%. PEG 0.03 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (15/100, Fail) — trailing P/E is well above the S&P 500 average of ~25, suggesting a premium valuation (P/E 89.1).
- Forward P/E 14.9 (down from trailing 89.1) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.03 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 1.12% — below bond yields — investors are paying a premium for expected growth rather than current earnings. Forward yield improves to 6.70% as earnings recover.
Overall SharesGrow Score: 43/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
15/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — ARKAY
Valuation Multiples
P/E (TTM)89.1
Forward P/E14.9
PEG Ratio0.03
Forward PEG0.03
P/B Ratio0.00
P/S Ratio0.62
EV/EBITDA0.0
Per Share Data
EPS (TTM)$0.80
Forward EPS (Est.)$4.78
Book Value / Share$0.00
Revenue / Share$114.66
FCF / Share$0.00
Yields & Fair Value
Earnings Yield1.12%
Forward Earnings Yield6.70%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$5.22 |
$7.54B |
$394M |
5.2% |
| 2017 |
$7.15 |
$8.33B |
$543M |
6.5% |
| 2018 |
$8.82 |
$8.82B |
$674M |
7.6% |
| 2019 |
$6.41 |
$8.74B |
$491M |
5.6% |
| 2020 |
$3.96 |
$7.88B |
$332M |
4.2% |
| 2021 |
$17.04 |
$9.52B |
$1.31B |
13.8% |
| 2022 |
$12.75 |
$11.55B |
$965M |
8.4% |
| 2023 |
$5.36 |
$9.51B |
$418M |
4.4% |
| 2024 |
$4.29 |
$9.54B |
$354M |
3.7% |
| 2025 |
$0.80 |
$8.71B |
$60.51M |
0.7% |
